iTeos Therapeutics Inc.
https://www.iteostherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From iTeos Therapeutics Inc.
Finance Watch: Verona Accesses Up To $650m As Ensifentrine Approval Deadline Nears
Public Company Edition: Verona Pharma arranged up to $400m in new debt and up to $250m in revenue-related financing ahead of its COPD drug launch. Also, Organon, Sobi and Pacira priced $1bn, $275.1m and $250m note sales, respectively. Marinus, Emergent and Ginkgo cut jobs.
New RUBY Results Boost GSK's Blockbuster Bid For Jemperli
The company’s PD-1 inhibitor Jemperli plus GSK's own PARP Zejula has scored a win in a late-stage endometrial cancer trial that could lead to a key label expansion.
GSK’s IO Backbone Jemperli Looks Stronger After OS Success
Jemperli has struggled to gain a presence in cancer immunotherapy so far, but GSK believes the PD-1 therapy can hold its own against Merck & Co’s mega-blockbuster Keytruda in a few key areas.
Roche’s Data Leak Reawakens Hopes For TIGIT Lung Cancer Drug
An “inadvertent disclosure” of data has done Roche’s share price no harm, but analysts are still unsure that its TIGIT immunotherapy can prove a threat to Merck’s all-conquering Keytruda.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice